About Us

Cancer Drug Resistance (CDR) is an international peer-reviewed, open access, online journal.

 
Aims and Scope
Cancer Drug Resistance is a quarterly published journal committed to the rapid publication of high quality, peer-reviewed, original researches. The journal publishes research articles, reviews, case reports, commentaries and letters on pharmacological aspects of drug resistance and its reversal, including drug design, drug delivery, drug distribution and cellular drug resistance. Molecular mechanisms of drug resistance also cover the cellular pharmacology of drug resistance such as influx and efflux pumps (including the ABC pumps), receptors and their ligands, cellular signaling pathways, drug activation and degradation (including Phase I and II metabolism), drug sequestration, target modification and DNA repair. Drug classes to be covered include DNA targeted drugs and antihormones as well as antibodies and protein kinase inhibitors. Both clinical and experimental aspects of drug resistance in cancer are included. 
 
Ownership
The journal is owned by OAE Publishing Inc.
 
Open Access
All articles published by CDR are made freely and permanently accessible online immediately from the date of publication. Articles are published under a Creative Commons Attribution 4.0 International License (CC BY). The CC BY allows for maximum dissemination and re-use of open access materials and is preferred by many research funding bodies. Under this license users are free to share (copy, distribute and transmit) and remix (adapt) the contribution for any purposes, even commercially, provided that the users appropriately acknowledge the original authors and the source.
Authors retain the copyright of their works as well as the rights to make certain uses of the works.
 
Editorial Board
For more information about the editorial team, please refer to Editorial Board.

 
Editorial Policies
All manuscripts submitted to CDR should adhere to OAE's Editorial Policies.
 
Peer Review
The journal adheres to rigorous peer review process and undergoes single-blind peer review. For more details, please refer to Editorial Process and Peer Review Guidelines.
 
Journal Information and Statistics
Launch date: 19 March 2018
Publication model: Open access
ISSN 2578-532X (Online)
Digital archive: Portico 
Frequency: Quarterly published
DOI: 10.20517/cdr
 
Contact
Please visit Contact Us for details about different queries.
Cancer Drug Resistance ISSN 2578-532X (Online)
Partners
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.